Are there any concerns with the use of IL-23 or IL-17 inhibitors in patients with a history of cutaneous squamous cell carcinoma (cSCC)?
Featuring April Armstrong, MD, MPH | Co-Director |
Chief, Division of Dermatology | Published October 19, 2021
Chief, Division of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, CA